FSD Pharma up on Canadian regulator's nod for human trials on MS drug

Quantum Biopharma

07/02/2023 16:02

** U.S.-listed shares of Canada-based drug developer FSD
Pharma Inc  HUGE.O  rises 5% to $1.28
    ** Co says Canada's health regulator has cleared the
application to begin human trials for its experimental drug to
treat multiple sclerosis    
    ** Multiple sclerosis is a neurological disease in which the
immune system attacks nerve cells surrounding the brain and
spinal cord, causing motor disabilities
    ** The drug candidate, LUCID-21-302, is being tested to 
prevent degradation of myelin, which coats nerve cells, a known
cause of multiple sclerosis  - co     
    ** Including session moves, stock has risen ~48% in the past
12 months
 (Reporting by Mariam E Sunny)
 ((Mariam.ESunny@thomsonreuters.com;))